ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.042,05
0,12%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
0,00%
Euro vs US Dollar
1,07145
-0,03%
Bitcoin
65.742,25
-1,35%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Salarius Pharmaceuticals Inc (SLRX)

  7. Salarius Pharmaceuticals Inc (SLRX) News

SLRX

Salarius Pharmaceuticals (SLRX)

Salarius Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SLRX
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202414h00GlobeNewswire Inc.Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitNASDAQ:SLRXSalarius Pharmaceuticals Inc
13/05/202422h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
22/03/202421h05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
06/03/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202422h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRXSalarius Pharmaceuticals Inc
22/02/202414h00GlobeNewswire Inc.Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesNASDAQ:SLRXSalarius Pharmaceuticals Inc
16/01/202414h00GlobeNewswire Inc.Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersNASDAQ:SLRXSalarius Pharmaceuticals Inc
03/01/202414h30GlobeNewswire Inc.Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNASDAQ:SLRXSalarius Pharmaceuticals Inc
09/11/202323h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
07/11/202314h30GlobeNewswire Inc.Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramNASDAQ:SLRXSalarius Pharmaceuticals Inc
27/10/202321h57Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SLRXSalarius Pharmaceuticals Inc
06/09/202323h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
10/08/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
10/08/202322h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRXSalarius Pharmaceuticals Inc
10/08/202322h05GlobeNewswire Inc.Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/08/202322h05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its ResourcesNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/07/202315h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/07/202314h30GlobeNewswire Inc.Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/06/202314h00GlobeNewswire Inc.Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid CongressNASDAQ:SLRXSalarius Pharmaceuticals Inc
08/06/202312h02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:SLRXSalarius Pharmaceuticals Inc
07/06/202313h28Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
01/06/202323h02Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:SLRXSalarius Pharmaceuticals Inc
26/05/202323h03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202322h34Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SLRXSalarius Pharmaceuticals Inc
16/05/202322h05GlobeNewswire Inc.Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
12/05/202314h00GlobeNewswire Inc.Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SLRXSalarius Pharmaceuticals Inc
11/05/202314h00GlobeNewswire Inc.Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:SLRXSalarius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SLRX

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
TG
MBG
MercedesBenz
TG
DTE
Deutsche Telekom
NASDAQ
TSLA
Tesla
COIN
BTCUSD
Bitcoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AMZN
Amazon.com
TG
BAYN
Bayer
USOTC
ADDYY
Adidas (QX)
TG
TUI1
Tui
TG
NOV
Novo Nordisk
CCOM
US500
US 500
NYSE
DIS
Walt Disney
DBI
TDXP
Tec DAX
CCOM
US100
US Tech 100
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten